Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Myelodysplastic Syndromes Clinical Trial

Official title:

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06462365
• Other study ID #: TRX103-01
• Status: Recruiting
• Phase: Phase 1
• Start date: April 8, 2024
• Est. completion date: April 15, 2027

Study information

• Verified date: April 2024
• Source: Tr1X, Inc.
• Contact: Tr1X Clinical Trials
• Phone: 858-255-4447
• Email: Tr1xClinicalTrials[@]Tr1x.bio
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: April 15, 2027
• Est. primary completion date: April 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)

2. Males and Females Age = 18 years.

3. Weight of = 35 Kg.

4. Karnofsky performance status = 70 %.

5. Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.

6. Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.

7. Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.

8. Have adequate organ function.

9. Subjects > 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score < 5.

10. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.

Exclusion Criteria:

1. Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.

2. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.

3. HIV positive.

4. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.

5. Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.

6. Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities.

7. Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.

8. Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).

9. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia, Adult B-Cell
• Acute Myeloid Leukemia in Remission
• Cancer Remission
• GvHD
• GVHD, Chronic
• GVHD,Acute
• Hematologic Malignancy
• Hematologic Neoplasms
• Hematopoietic Stem Cell Transplant
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Leukemia-Lymphoma, Adult T-Cell
• Myelodysplastic Syndromes
• Neoplasms
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• TRX103
TRX103 infusion via central line.

Locations

Country	Name	City	State
United States	City of Hope	Duarte	California

Sponsors (1)

Lead Sponsor	Collaborator
Tr1X, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.		Up to a year
Primary	Safety of TRX103 determined by stem cell engraftment and donor chimerism after HSCT measured by absolute neutrophil counts and percent donor chimerism.		Up to day 42
Primary	Safety of TRX103 determined by negative Replication Competent Lentivirus (RCL).		At 3-month, 6-month, and 1-year.
Secondary	Incidence of Grade II-IV acute GvHD (aGvHD).		Day 0 to Day +100 day
Secondary	Incidence of Grade III-IV acute GvHD (aGvHD).		Day 0 to Day +100 day
Secondary	Incidence and severity of chronic GvHD (cGvHD)		Day +100 through Day +365
Secondary	Overall survival at Day +365.		Up to a year